Causality assessment of adverse drug effects: When is rechallenge ethically acceptable? (multiple letters) [8]

Lancet

Volumn 354, Issue 9179, 1999, Pages 683-

  Po, A L W ^a   Kendall, M J ^a   Pinto, Y M ^a   Van Gelder, I C ^a   Crijns, H J G M ^a   Heeringa, M ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE;

DRUG INDICATION; DRUG RECHALLENGE; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HUMAN; INFORMED CONSENT; LETTER; MEDICAL ETHICS; PRIORITY JOURNAL; STANDARD;

EID: 0033592193     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)77665-0     Document Type: Letter

References (5)

1. YM Pinto van Gelder 1C Hearings M Crijns HJGM. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 353 1999 980
2. FE Simons NJ Bergma WT Watson KJ Simons The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 98 1996 1062 1064
3. A Li Wan Po WY Zhang What lessons can we learn from the withdrawal of mebifradil from the market? Lancet 351 1998 1829 1830
4. T Giraud QT lengthening and arrhythmias associated with fexofenadine. Lancet d353 1999 2072
5. DC Hadorn Setting health priorities in Oregon: cost-effectiveness meets the rule of rescue. JAMA 265 1991 2218 2225